

Index

A

- A9, 55
- A10, 55
- A77636, 72
- A83959, 74
- α_{1A} -adrenoceptor, 230
- α_{2A} -adrenoceptor, 228
- AADC. *See* Aromatic acid decarboxylase (AADC)
- α_1 -adrenoceptor, 219
- α_2 -adrenoceptors, 218
- Aberrant salience, 15
- ABT-431, 74
- Acetylcholine efflux, 108
- ACh efflux, 97
- ACP-103, 95, 99
- Acute amphetamine treatment, 373
- Acute NMDA antagonists, 373
- Adenylate cyclases, 57, 59
- Adherence, 130
- Adiposity, 137, 142, 148, 149, 153, 154, 158
- Adverse effects, 248
- Affective flattening, 371
- Affinity states, 8
- Agonist, 57
- 2548A/G Polymorphism, 228
- Agranulocytosis, 89, 173, 174, 255
- Aisulpride, 168
- Akathisia, 169, 218
- Akinesia, 169
- AKT1, 377
- Allosteric antagonist, 58
- Allosteric ligands, 58
- Allosteric targeting of dopamine receptors, 58
- Alogia, 364, 369
- Alpha-calcium/calmodulin-dependent protein kinase II (alpha-CaMKII+ or–), 107
- Alpha-methyl-para-tyrosine (α MPT), 5
- Alstonine, 107
- Altanserin, 96
- γ -Aminobutyric acid (GABA), 372
- Amisulpride, 39, 90, 91, 254, 363
- Amphetamine, 2, 31, 366
- Amphetamine-induced dopamine release, 5, 12
- Amphetamine-induced locomotor activity, 95
- Amphetamine-stimulated DA release, 15
- α MPT. *See* Alpha-methyl-para-tyrosine (α MPT)
- α MPT-induced DA depletion, 5
- Amygdala, 67
- Amygdala lesions, 380
- Anhedonia, 14, 369, 371
- Animal models, 137, 142, 152, 155
- ANKS1B, 225
- Antagonist, 57
- Anticholinergic, 174
- Anticholinergic activity, 250
- Antidopaminergic effects, 249
- Antioxidant, 130
- Antipsychotic drug (APD), 54, 89, 137, 147, 149, 150, 152, 157
 - aripiprazole, 140, 141, 149–151, 157, 158
 - chlorpromazine, 139
 - clozapine, 139–147, 149–154
 - fluphenazine, 140
 - haloperidol, 140–144, 147, 148, 150, 152
 - loxapine, 140
 - molindone, 139
 - olanzapine, 139–157
 - pimozide, 140
 - quetiapine, 140, 141
 - risperidone, 140–145, 147–154, 157
 - sertindole, 140
 - sulpirid, 143

Antipsychotic drug (APD) (*cont.*)
 thiothixene, 140
 ziprasidone, 139–152, 154, 157, 158
 zotepine, 140
 Antipsychotic-induced weight gain, 137, 142,
 149, 154, 155, 157
 Antipsychotics, 31
 Antipsychotic weight gain, 143
 Apathy, 369
 APD. *See* Antipsychotic drug (APD)
 APS. *See* Attenuated Psychotic Symptoms
 (APS)
 Arachidonic acid, 60
 Aripiprazole, 32, 90, 91, 173, 254, 272
 ARMS. *See* At Risk Mental States (ARMS)
 Aromatic acid decarboxylase (AADC), 3
 Asenapine, 89, 91, 173, 254, 272
 Associative learning, 365
 Associative striatum (AST), 4, 11, 14
 Aticholinergic side effects, 169
 Antihistaminic action, 169
 At-Risk, 10
 At Risk Mental States (ARMS), 126
 Attention/vigilance, 371
 Attenuated Psychotic Symptoms (APS), 126
 Atypical, 31
 Atypical antipsychotics, 205, 270, 351, 363
 adjunctive therapy, 189, 191–194
 depression, 197
 dopamine, 197, 198, 201, 203
 GSK3, 197
 maintenance, 194, 195
 mania, 197
 monotherapy, 188–197
 norepinephrine, 197, 198
 relapses, 195
 serotonin, 197, 202, 203
 Atypical APDs, 88, 89, 363
 Auditory hallucinations, 166, 369
 Autoreceptors, 55, 59

B

Bacterial, 381
 Barbiturates, 246
 β -arrestin, 57
 β -arrestin 2, 60
 β -arrestin/Akt pathway, 61
 Basic symptoms, 126
 BDNF. *See* Brain-derived neurotrophic factor
 (BDNF)
 Behavioral read-outs, 369
 Benperidol, 254

$\beta\gamma$ signaling, 56
 $\beta\gamma$ subunits, 56
 Bifeprunox, 66, 101
 Bioavailability, 279
 Biodegradable microparticles, 280
 Biodegradable polymers, 283
 Biodegradable systems, 281
 Bipolar disorder, 205
 adjunctive therapy, 190
 agitation, 192
 depression, 188, 189, 192, 193, 195,
 196, 198
 maintenance, 189, 193, 205
 mania, 188–192, 195, 198, 199
 relapse, 188, 193, 196, 197
 Birth complications, 99
 BLIPS. *See* Brief Limited Intermittent
 Psychotic Symptoms (BLIPS)
 Blonanserin, 91
 Blunted affect, 166
 Brain-derived neurotrophic factor (BDNF), 95,
 228, 352
 Brief Limited Intermittent Psychotic
 Symptoms (BLIPS), 126
 Bromperidol, 255
 Burst firing, 15

C

CA1, 17
 Calbindin-containing, 92
 cAMP/PKA pathway, 68
 cAMP/PKA signaling, 68
 cAMP response element binding protein
 (CREB), 65, 67
 Candidate genes, 216
 Cannabinoids, 347
 (+ or-)-3-(2-carboxypiperazin-4-yl)-propyl-1-
 phosphonic acid (CPP), 106
 Cardiovascular disease (CVD), 136
 Cardiovascular side effects, 167
 Cariprazine, 97
 Catechol-*O*-methyltransferase (COMT),
 215, 222, 376, 377
 CATIE. *See* Clinical Antipsychotic Trials of
 Intervention Effectiveness (CATIE)
 CATIE trial, 220
 Cellular resilience, 197
 Bcl-2, 203, 204
 Cerebral blood volume (CBV), 17
 Cerebrospinal fluid (CSF), 341, 343, 348
 glycine, 348, 349
 Cesarean section, 383

- [¹¹C]FLB 457, 9
 Chemokines, 352
 Chlorpromazine, 29, 54, 64, 89, 91, 169, 255, 269, 340
 Chlorpromazine equivalents, 271
 Chlorprothixene, 255
 5-Choice serial reaction time test, 365
 Cholinergic systems, 372
 Chronic amphetamine treatment, 373
 Chronic dyskinesia, 169
 Chronic NMDA receptor antagonist, 373
 [¹¹C] L-DOPA, 3
 Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 32, 167
 Clorpromazine, 168
 Clozapine, 34, 89, 170, 218, 219, 255, 270, 363
 [¹¹C]NNC 112, 9
 CNTNAP5, 225
 CNTRICS. *See* Cognitive Neuroscience Treatment Research To Improve Cognition in Schizophrenia (CNTRICS)
 Cognition, 90, 271
 Cognitive behavioral therapy, 131
 Cognitive deficits, 17, 54, 269
 Cognitive disturbances, 14
 Cognitive enhancers, 388
 Cognitive flexibility, 90
 Cognitive functioning, 167
 Cognitive impairment, 90, 109
 Cognitive Neuroscience Treatment Research To Improve Cognition in Schizophrenia (CNTRICS), 364
 Cognitive symptoms, 16, 36, 169
 COMT. *See* Catechol-*O*-methyltransferase (COMT)
 Constipation, 173
 Construct validity, 368
 Continuous infusion, 277
 Controlled clinical trials, 127
 Conversion, 129
 Conversion risk, 132
 Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS), 32, 167
 Co-twins, 10
 [¹¹C]PE21, 9
 [¹¹C]PHNO, 7
 [¹¹C]raclopride, 5
 CREB. *See* cAMP response element binding protein (CREB)
 [¹¹C]SCH 23390, 9
 CSF. *See* Cerebrospinal fluid (CSF)
 -759 C/T, 227
 Cytochrome P450 enzymes, 244
 CUtLASS. *See* Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS)
 Cyclooxygenase, 60
 CYP1A2, 226, 244
 CYP3A4, 244
 CYP2C19, 244
 CYP2D6, 226, 244
 Cytochrome P450 enzymes, 217
 Cytokine-mediated inflammation, 99
 Cytokines, 352
 Cytosine arabinoside (Ara-C), 381
- D**
 DA. *See* Dopamine (DA)
 DAG. *See* 1,2-Diacylglycerol (DAG)
 DALYs. *See* Disability-adjusted life years (DALYs)
 DARPP-32, 67
 DAT. *See* Dopamine transporter (DAT)
 DAT KO, 377
 D_{2/3} binding potential, 4
 D-cycloserine, 347
 D₁/D₂ heterodimer, 71
 Decanoate, 276
 Default mode network (DMN), 104
 Delayed non-match to sample/position, 365
 Delayed-onset, 39
 Delusions, 14, 364, 369
 Depolarization blockade, 37
 Depot formulations, 278
 Depot medication, 7
 Depressive symptoms, 129
 Developmental vitamin D deficiency, 383
 DHA. *See* Docosahexaenoic acid (DHA)
 DHBE. *See* Dihydro-β-erythroidine (DHBE)
 D₂ high, 8
 DHX. *See* Dihydropyridine (DHX)
 Diabetes, 229
 Diabetic ketoacidosis (DKA), 137, 138, 149, 151, 152, 157
 Diabetogenic effects, 173
 1,2-Diacylglycerol (DAG), 69
 Diffusion, 284
 Diffusion-controlled release, 284
 Dihydropyridine (DHX), 62
 Dihydro-β-erythroidine (DHBE), 375
 (+ or -)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride
 DOI, 94
 Dinapsoline, 72
 Direct nigrostriatal pathway, 55

- Disability-adjusted life years (DALYs), 166
DISC1 deletion, 377
Discrimination, 132
Disease burden, 132
Disrupted in schizophrenia-1 (DISC-1), 376
Dizocilpine, 366, 367
Dizocilpine (MK-801), 93
DKA. *See* Diabetic ketoacidosis (DKA)
D₁-like signaling, 66
D₂-like signaling, 59
D_{2L}, long, 55
DMN. *See* Default mode network (DMN)
D_{2/3} occupancy, 5
Docosahexaenoic acid (DHA), 130
DOI, 95
Dopamine (DA), 97, 301, 304–314, 316, 318, 321–324
 D₁, 58, 307–309, 322, 323
 receptor binding, 10
 receptor density, 30
 receptors, 13, 218
 signaling, 68
 D₂, 305, 307, 309, 316, 321, 322
 antagonist, 61, 340
 partial agonists, 34, 64
 receptor antagonism, 89
 receptor binding, 270
 receptor blockade, 33
 receptor density, 29
 receptor occupancy, 12, 278
 receptors, 2, 29, 37, 88, 215, 270, 341
 receptor supersensitivity, 30
 D_{2/3}, 308–312, 321, 322
 receptors, 4
 D₃, 13, 55, 58, 220, 309, 316, 321
 receptor mRNA expression, 343
 receptors, 7, 109
 D₄, 13, 35, 55
 receptors, 35
 D₅, 307, 323
depletion, 10, 12
D_{2s}
 receptors, 61
 short, 55
hyperactivity, 2
hyperfunction, 29
hypoactivity, 2
hypofunction, 31
hypothesis, 2, 56
 of schizophrenia, 2, 270
mesolimbic neurons, 40
MRI, 318
neuron, 15
neurotransmission, 2
PET, 301, 304, 307–309, 311, 312, 316, 318, 319, 321–323
 phMRI, 324
 receptor occupancy, 252
 release, 4, 62
 SPECT, 301, 307, 308, 312, 314, 318, 319, 323
 spectroscopy, 324
 stabilizer, 64
 synthesis, 3, 4, 30, 62
 synthesis capacity, 4, 11, 12
 terminals, 6
Dopaminergic, 300–302, 304, 307, 308, 310, 311, 313, 314, 321, 322, 324
 PET, 301
Dopaminergic signaling, 55
Dopamine transporter (DAT), 6, 9, 60, 221
Dorsal raphe (DR), 92
DPP6, 227
DR4004, 109
DRD2, 217, 219, 221
DRD3, 217, 221
DRD4, 217
D2R tg, 378
Drug–drug interaction, 243
Drug-induced weight gain, 214
Drug release mechanisms, 283
Drug treatments, 154
DSM-5, 126
Dual-isotope SPECT, 6
Dysbindin1, 215
Dysbindin1 (DTNBP1), 224
Dystonia, 218
- E**
Early Initial Prodromal States (EIPS), 126
Executive functions, 367
Eicosapentaenoic acid (EPA), 130
EIPS. *See* Early Initial Prodromal States (EIPS)
Elimination, 244
EN1. *See* Engrailed1 (EN1)
Endophenotype, 376
Endophenotypic biomarker, 343
Engrailed1 (EN1), 224
Entorhinal cortex lesions, 379, 380
EPA. *See* Eicosapentaenoic acid (EPA)
EPMS/TD, 174
EPS. *See* Extrapyrarnidal side effects (EPS)
ERK. *See* Extracellular signal-regulated kinase (ERK)
Erosion, 284
Excitatory amino acid transporter 4 gene (SLC1A6), 225

Executive functions, 90, 365
 Extracellular signal-regulated kinase (ERK), 60
 Extrapyramidal side effects (EPS), 33, 56, 88, 166–167, 218
 liability, 36
 Extrapyramidal symptoms, 249
 Extrastriatal DA, 9
 Extrastriatal D₂ receptor, 9

F

Face validity, 368
 [¹⁸F]DOPA, 3, 30
 [¹⁸F]DOPA uptake, 4
 [¹⁸F]fallypride, 7
 First-and second-generation, 270
 First-pass metabolism, 279
 Flattened affect, 14
 Fluorodopamine, 301
 Flupenthixol, 256
 Fluphenazine, 256, 272
 Fluphenazine decanoate, 272
 Fluspirilene, 256
 Forepaw treading, 375
 FTO gene, 228
 Functional selectivity, 57

G

GABA, 372
 GABA_A receptors, 67
 GABAergic interneurons, 17, 88, 92
 G $\alpha_{i/o}$, 58
 G α_o , 67
 G α_{olf} , 66
 G α_q , 67
 G $\alpha_{q/11}$, 69
 G α_s , 58, 66
 G $\alpha_{s/olf}$, 55, 66
 G α subunits, 56
 G $\beta\gamma$, 60
 G $\beta\gamma$ subunits, 59
 Gene–environment interactions, 216, 231
 Gene expression profiling, 350
 General validity criteria, 368
 Genetic, 364, 372
 Genetic models, 376
 GIRK, 59
 GLAST KO, 377
 GLI2 gene, 227
 Global functioning, 129
 Glutamate metabotropic receptor-3 gene, 224
 Glutathione, 130
 Glycine, 347

Glycine transporter type 1 (GlyT1), 347, 348
 Glycogen synthase kinase 3 (GSK3), 60
 GlyT1 inhibitor, 348
 GlyT1 occupancy, 349
 GNB3, 228
 GPCR. *See* G protein-coupled receptor (GPCR)
 G-protein beta3 subunit, 228
 G-protein beta3 subunit gene (GNB3), 223
 G protein-coupled receptor (GPCR), 54
 G protein-coupled receptor kinases (GRKs), 57–58
 G protein heterotrimers, 64
 G protein-independent pathways, 57
 G proteins, 68
 G protein signaling (RGS) proteins, 58
 GRIA4, 225
 GRK/arrestin pathway, 60
 GRKs. *See* G protein-coupled receptor kinases (GRKs)
 Stereotypy, 367
 GTP, 59
 GTP γ S binding, 66
 GTP hydrolysis, 58
 Guanine-nucleotide, 62

H

Hallucinations, 14, 364
 Hallucinogens, 375
 Haloperidol, 32, 33, 89, 91, 140, 169, 256
 Haloperidol decanoate, 272
 Haplotype analysis, 216
 Head twitches, 375
 Heparin sulfate proteoglycan 2 (HSPG2), 227
 Heterodimers, 58
 Hippocampal pyramidal neurons, 88
 Hippocampus, 17, 90
 Histamine H₁ receptor, 219
 HLA-DBQ1, 230
 Holeboard exploration, 365
 Homer-1, 224
 Homovanillic acid (HVA), 343
 [³H] RO5013853, 349
 HSPG2. *See* Heparin sulfate proteoglycan 2 (HSPG2)
 5-HT₂, 271
 5-HT₃, 92
 5-HT_{2A/D} 2 ratio, 90
 5-HT_{2A} inverse agonists, 93
 5-HT_{1A} partial agonists, 89, 97, 101
 5-HT_{2A} receptor, 10, 36, 215, 217
 5-HT_{1A} receptors, 218
 5-HT_{2C} receptor promoter polymorphism (-759 C/T), 227

HTR6, 217
 HTR1A, 217, 221
 HTR2A, 217
 HTR2C, 217
 HTR3E, 222
 5-HT₇ receptor deletion, 109
 5-HT₇-receptors, 169
 5-HT₂ receptors, 341
 5-HT transporter gene (SLC6A4), 221
 HVA. *See* Homovanillic acid (HVA)
 6-Hydroxydopamine (6-OHDA), 66
 9-Hydroxyrisperidone, 259
 Hyperdopaminergic, 304, 310, 312
 Hyperdopaminergic function, 29
 Hyperglycaemia, 174
 Hyperkinesia, 169
 Hyperlipidaemia, 174
 Hyperlocomotor activity, 370
 Hyperprolactinemia, 37, 167
 Hypersalivation, 173, 174
 Hypertonia, 169
 Hypodopaminergia, 31
 Hypodopaminergic, 308
 Hypothesis-free biomarker approach, 350
 Hypotonia, 169

I

[¹²³I]epidepride, 9
 [¹²³I]IBZM, 4–6, 12
 Iloperidone, 89, 91, 257, 272
 Imaging, 300–310, 313–317, 320–324
 D₁, 302, 307, 308, 322
 D₂, 302, 310, 322
 D_{2/3}, 302, 308–310, 322
 D₃, 310
 fMRI, 320
 MRI, 304
 PET, 300–303, 305, 307–309, 315–317, 322–324
 phMRI, 300, 320
 SPECT, 300, 302, 305, 306, 315, 317, 322, 323
 spectroscopy, 300, 315, 318
 Increased insulin, 153
 Indirect pathway, 55
 Inducers, 247
 Induction, 244
 Inhibition, 244
 Inhibitors, 246
 INI, 105
 Injectable olanzapine, 275
 Inositol 1,4,5-trisphosphate (IP₃), 69
 Insomnia, 173

Insulin resistance, 137, 138, 149, 150, 152, 153, 155
 Insulin secretion, 152, 153
 Integrated Psychological Intervention group, 131
 Integrative Therapy (IT), 131
 Interleukin (IL)-6, 99
 Internalization, 72
 Intradimensional/extradimensional shift, 365
 Intrinsic efficacy, 57
 Inverse agonist, 57
 IP₃. *See* Inositol 1,4,5-trisphosphate (IP₃)
 Isolation rearing, 381

K

Kamin blocking, 365
 K⁺ currents, 59
 Ketamine, 93, 347, 366
 Kir3, 59

L

Late Initial Prodromal States (LIPS), 126
 Latent inhibition, 365
 Lateral globus pallidus, 55
 LD. *See* Linkage disequilibrium (LD)
 L-DOPA, 3
 L-DOPA-induced psychosis, 100
 L-DOPA psychosis, 100
 Leptin, 228
 Lesion, 372
 Lesion-based, 364
 Lesion models, 376
 Levomepromazine, 257
 Lifestyle, 136, 138
 Limbic selectivity, 37
 Linkage disequilibrium (LD), 216, 223
 Lipoxigenase, 60
 LIPS. *See* Late Initial Prodromal States (LIPS)
 L, N, and P/Q type, 69
 L, N channels, 60
 Locomotor inhibition, 64
 Loss of motivation, 14
 Lower lip retraction, 375
 Loxapine, 272
 LSD. *See* Lysergic acid diethylamide (LSD)
 Lu AE58054, 108
 Lurasidone, 91, 101
 LY379268, 93
 Lymphocyte, 342
 Lysergic acid diethylamide (LSD), 95, 375

M

M100907, 93, 94, 106
 Major depression, 387
 Major thought disorders, 364, 369
 MAM. *See* Methylazoxymethanol acetate (MAM)
 MAPK pathway, 67
 MAPK signaling, 67
 Maternal infections, 99
 Maternal separation, 381
 Maturation, 381
 MDR1(ABCB1), 215
 Measurement and Treatment Research to Improve Cognition in Schizophrenia, 364
 Mechanistic biomarker, 344
 Medial globus pallidus, 55
 Median raphe, 88
 Medication adherence, 269, 286
 Medications, 270
 Medium spiny neurons (MSNs), 13, 55
 MEIS2, 229
 Melperone, 91, 257
 Membrane permeability, 130
 Mescaline, 375
 Mesolimbic, 370
 Mesolimbic pathway, 2
 Metabolic side effects, 88
 Metabolic syndrome, 167, 178, 250
 Metabolomic profiling, 351
 Metabolomics, 351
 Metabotropic glutamate_{2/3} (mGlu_{2/3}) receptor agonists, 93
 Methylazoxymethanol acetate (MAM), 381
 mGlu₂ agonists, 93
 mGluR5 KO, 377
 Microdialysis, 366
 Microparticles, 280
 Midbrain DA neuron firing, 39
 miRNA, 216
 Missense or non-synonymous mutation, 216
 Mitogen activated protein (MAP) kinases, 59
 MK-801, 367
 MK-801-induced locomotor activity, 94
 Molindone, 272
 Monozygotic twins, 10, 215
 Moodstabilizers, 130
 Morris water maze, 365
 MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), 379
 MSNs. *See* Medium spiny neurons (MSNs)
 [¹⁹⁹mTc]TRODAT, 6
 Multi-analyte serum profiling, 355

N

Na⁺ channels, 60
 Na⁺/H⁺-exchanger, 59, 73
 Na⁺-K⁺-ATPase, 73
 N-desmethylclozapine, 91, 106
 Negative, 166
 Negative symptoms, 14, 54, 129, 269, 369
 Neonatal ventral hippocampal (nVHP) lesion, 379
 Neuregulin-1 (NRG-1), 376
 Neurobiology
 of 5-HT_{1A} receptors, 101
 of 5-HT_{2A} receptors, 92
 of 5-HT_{2C} receptors, 104
 Neurodevelopmental, 364, 372
 Neurodevelopmental models, 379
 Neuroimaging, 323
 Neuroleptic syndrome, 249
 Neuron firing, 62
 Neuroprotective, 130
 Neurotrophins, 352
 NFκB, 99
 Nigrostriatal, 55
 Nigrostriatal dopamine systems, 370
 Nigrostriatal pathway, 2
 Nitric oxide synthase (NOS), 381
 N-methyl-D-aspartic acid (NMDA), 67
 antagonists, 17
 hypofunction, 17
 receptor antagonists, 93, 375
 receptor blocker, 347
 receptors, 347
 receptor subunit, 218
 N-n-propyldihydroxidine (PrDHX), 62
 NNT. *See* Number needed to treat (NNT)
 Non-adherence, 273
 Noncompliance, 89, 168
 Nonhuman primate models, 363
 Noradrenergic side effects, 169
 Norepinephrine transporter (SLC6A2), 222
 NOS. *See* Nitric oxide synthase (NOS)
 NR2A, 109
 NR2B subunits, 109
 N-type Ca²⁺ channels, 60
 Number needed to treat (NNT), 127
 Nurr1, 377

O

Obesity, 136–139, 141, 148, 150, 154, 155, 157
 Olanzapine, 32, 91, 167, 170, 227, 257, 272, 363

Open field exploration, 365
 Orthostatic dysregulation, 174
 Orthosteric ligands, 58

P

Paliperidone (9-hydroxyrisperidone), 89, 91, 96, 257, 275
 Paranoia, 369
 Paranoid delusions, 166
 Parkinson's disease (PD), 61, 66
 Partial agonist, 57, 254
 Partial agonist (–)3-PPP (preclamol), 62
 Parvalbumin, 92
 Passive systems, 279
 PCP. *See* Phencyclidine (PCP)
 PCP-induced hyperlocomotion, 94
 PDE-7, 224
 Perazine, 258
 p-ERK, 68
 Perospirone, 96, 101
 Perphenazine, 32, 258, 271, 272
 Perseveration, 369, 371
 Personalized approaches, 179
 PET. *See* Positron emission tomography (PET)
 PFC. *See* Prefrontal cortex (PFC)
 P-glycoprotein, 215
 P-glycoprotein gene (ABCB1), 219
 Pharmacodynamic drug–drug interactions, 247
 Pharmacokinetic drug–drug interactions, 244
 Pharmacological, 372
 Pharmacological models, 372
 Phase 1 metabolism, 244
 Phasic dopamine burst firing, 15
 Phencyclidine (PCP), 93, 347, 366, 367
 (+)-PHNO, 8
 Phosphatidylcholine, 60
 Phosphatidylinositol 4,5-bisphosphate (PIP₂), 69
 Phospholipase A2, 60
 Phospholipase C (PLC), 69
 Phospholipases, 59
 Pimavanserin (ACP-103), 95
 Pimozide, 258, 272
 Pipamperone, 258
 Pituitary lactotrophs, 63
 PKA, 66, 68
 PKC. *See* Protein kinase C (PKC)
 PLC. *See* Phospholipase C (PLC)
 PLC-β, 69
 PLC-β2, 70
 PLC-γ, 70
 PLC/G₂θ signaling, 71
 PLGA, 281
 Poly (ε-caprolactone), 283

Polymorphism, 222, 227
 Polypharmacy, 175
 Polyunsaturated omega-3 fatty acids (PUFAs), 129
 Positive, 166
 Positive symptoms, 14, 54
 Positive symptoms, 369
 Positron emission tomography, 252
 Positron emission tomography (PET), 3, 29, 341
 Postinjection syndrome, 275
 Postmortem studies, 8
 Postnatal blockade of NMDA receptors, 374
 Postnatal MK-801 treatment, 374
 Postnatal PCP treatment, 374
 Potassium channels, 59
 Potency, 286
 PPI disruption, 376
 P/Q-type Ca²⁺ channels, 60
 PrDHX. *See* *N-n*-propylidihydroxidine (PrDHX)
 Pre-attentional/-cognitive processes, 371
 Prediabetes, 137, 138
 Predictive validity, 369
 Prefrontal cortex (PFC), 14, 90
 Prefrontal cortex lesions, 380
 Prefrontal cortical DA, 9
 Prefrontal cortical regions, 9
 Pregnane X receptor-mediated, 246
 Prenatal corticosterone or dexamethasone treatment, 382
 Prenatal exposure to repeated restraint stress, 382
 Prenatal exposure to variable stress, 382
 Prenatal IL-6 exposure, 383
 Prenatal influenza exposure, 382
 Prenatal LPS exposure, 382
 Prenatal MAM treatment, 383
 Prenatal poly(I:C) exposure, 382
 Prenatal protein deprivation, 383
 Prenatal stress, 381
 Prenatal turpentine exposure, 383
 Prepulse inhibition (PPI), 94, 365
 Presynaptic, 55
 Presynaptic/autoreceptor, 59
 Prenatal MK-801 treatment, 374
 Preventive efforts, 127
 Primary negative symptoms, 31, 370
 PRKAR2B, 229
 Problem solving, 371
 Processing speed, 371
 Prodromal phase, 11
 Prodromal states, 10
 Prodromal symptoms, 15, 129
 of schizophrenia, 30
 Prodrome, 125
 Prolactin, 62, 89, 229, 271, 343

- Prolactin elevations, 88
 Prolactin increase, 174
 Pro-melanin-concentrating hormone, 229
 Promoter SNP, 221
 Prospective naturalistic study, 130
 Protein kinase B (Akt), 60
 Protein kinase C (PKC), 69
 Proteomic profiling, 351
 Prothipendyl, 258
 Prphenazine, 167
 Psilocybin, 375
 PsychINDx™, 351
 Psychomotor agitation, 369
 Psychopharmacological models, 364
 Psychotomimetic, 94
 PUFAs. *See* Polyunsaturated omega-3 fatty acids (PUFAs)
- Q**
- QTc prolongation, 173, 174, 219, 249
 Quality of life, 173
 Quetiapine, 32, 89, 91, 167, 170, 258, 272
 Quinpirole, 63
- R**
- Radial arm maze, 365
 Radiotracer, 5
 Randomized, 127
 Rapid dissociation, 37
 Reasoning, 371
 Receptor heterodimers, 71
 Receptor internalization and trafficking, 72
 Receptor oligomerization, 67
 Receptor reserve, 57
 Reeler, 378
 Reward prediction error, 15
 RG1678, 348
 Risperidone, 32, 89, 91, 140, 170, 227, 259, 271, 272, 363
 Risperidone depot, 275
 Risperidone microspheres, 272
 Ritanserin, 100, 107
 Ro 04-6790, 108
 Rodent models, 363, 372
 Rodent species, 363
 Rsperidone, 167
- S**
- S33804, 97
 Saliency, 15, 40
 Saliency attribution, 15
 SAPK/JNK. *See* Stress-activated protein kinase/Jun amino terminal kinase (SAPK/JNK)
- SB228357, 106
 SB242084, 106, 107
 SB269970, 109
 SB724457, 108
 SB2060553, 107
 SB-656104-A, 109
 SCH 23390, 99
 Schizophrenia, 29, 125, 138, 157, 350
 Schizotypal personality disorder (SPD), 12
 Schizotypal traits, 12
 Schizotypes, 12
 Scopolamine, 375
 Scratching, 375
 Secondary negative symptoms, 32, 370
 Second generation antipsychotics, 130
 Second-generation APD, 89
 Second messenger cAMP, 56
 Sedation, 169, 174
 Seizures, 174
 Selective D₃ antagonists, 97
 Sensorimotor gating, 365
 Sensorimotor striatum, 11
 Sentinel (safety) biomarkers, 345
 Ser311cys, 222
 Ser9gly, 222
 Serotonin (5-HT) receptors, 88
 Sertindole, 32, 91, 259, 363
 Sexual dysfunction, 167, 176
 Signaling complexes, 58
 Signaling pathways, 54, 74
 Signalsome, 58
 Signal transduction, 197
 - GSK3, 200, 201
 - protein kinase C (PKC), 199, 200, 204
 - Wnt, 200, 201
 Single-photon emission computed tomography (SPECT), 3, 29, 341
- SKF81297, 67
 SKF83822, 71
 SKF83959, 71
 SLC6A4, 217
 SLC22A23, 230
 SLC26A9, 225
 Smtoms, 166
 SMST, 14
 SNc. *See* Substantia nigra pars compacta (SNc)
 SNr. *See* Substantia nigra pars reticulata (SNr)
 Social behavior, 365
 Social cognition, 14, 371
 Social interaction, 365
 Social withdrawal, 166, 369
 SOD2. *See* Superoxide dismutase (SOD2)
 Somnolence, 173
 SPD. *See* Schizotypal personality disorder (SPD)

- SPECT. *See* Single-photon emission computed tomography (SPECT)
- Speed and onset of antipsychotic action, 39
- Splice variants, 55
- SR43468B, 96
- SR43469B, 95
- SR46349B, 96
- Stage-dependent approaches, 179
- Stereotyped behavior, 370
- Stereotypy, 365
- Stigma, 132
- Stress-activated protein kinase/Jun amino terminal kinase (SAPK/JNK), 60
- Striatal D₂ receptors, 6
- Striatum, 6
- Substance abuse, 274
- Substantia nigra, 9, 54, 88, 93
- Substantia nigra pars compacta (SNc), 14
- Substantia nigra pars reticulata (SNr), 14
- Suicide, 89
- Sulpiride, 90, 91, 259
- Superoxide dismutase (SOD2), 218, 226
- Surrogate biomarker, 345
- Surrogate markers, 343
- Susceptibility genes, 376
- Sustained attention vigilance, 365
- Synaptic plasticity, 203
neurotrophins (NTs), 202
- Synaptogenesis, 381
- T**
- Taq1A, 222
- Tardive dyskinesia (TD), 31, 38, 56, 89, 178, 214, 218, 226, 249, 278
- Target phenotypes, 216
- TD. *See* Tardive dyskinesia (TD)
- Temporal cortex, 9
- Thalamus, 9
- Therapeutic reference range, 252
- Therapeutic window, 252
- Thioridazine, 259, 272
- Thiothixene, 272
- TNF- α , 99
- Tocopherol (Vitamin E), 130
- Tolerance, 278
- Tonic firing of dopamine neurons, 15
- Transdermal delivery systems, 279
- Transdermal patch, 279
- Transition rate, 127
- Translational medicine, 346
- Transthyretin, 352
- Tremor, 169
- Trifluoperazine, 272
- Trihexyphenidyl, 375
- TRPM1, 225
- Twins, 10
- Type 2 diabetes, 137–139, 149–151, 157
- Typical, 31
- Tyrosine hydroxylase, 5, 59, 93
- U**
- Ultra High Risk Individuals (UHR), 126
- Upregulation of postsynaptic D2 receptors, 278
- V**
- Val/met COMT polymorphism, 224
- Ventral tegmental area (VTA), 14, 92
- Ventral tegmental dopaminergic neurons, 88
- Ventral tegmentum, 55
- Verbal learning, 371
- VeriPsych™, 354
- VGF peptide, 352
- Viral infections, 381
- Visual, 369
- Visual hallucinations, 375
- Visual learning and memory, 371
- VNI, 105
- Voltage-dependent Ca²⁺ channels, 69
- VST, 14
- VSV, 105
- VTA. *See* Ventral tegmental area (VTA)
- W**
- WAY-100635, 101, 102
- WAY-163909, 105
- Weight gain, 88, 137, 139–142, 147–150, 152–155, 157, 169, 227, 250
- Withdrawal from amphetamine, 373
- Withdrawal from NMDA antagonists, 373
- Working memory, 90, 365, 371
- World Health Report, 126
- X**
- XKR4, 225
- Y**
- Y-maze, 365
- Z**
- Ziprasidone, 32, 89, 91, 170, 260, 272
- ZNF202, 226
- ZNF804A, 224
- Zotepine, 32, 91, 260
- Zprasadone, 167
- Zuclopenthixol, 260